As psychedelics continue to emerge from the fringes of experimental science into the mainstream of mental health treatment, a major hurdle has consistently hampered their path to clinical integration: the lack of standardized methodology. Now, an international consortium of researchers led by McGill University, Imperial College London, and the University of Exeter has introduced a new framework designed to bring scientific rigour and reliability to this rapidly evolving field. By addressing the critical influence of environmental and psychological factors, this initiative marks a pivotal shift in how the medical community evaluates the therapeutic potential of substances like MDMA and psilocybin.
For years, the psychedelic clinical trial landscape has grappled with a fundamental flaw: the failure to systematically account for "set and setting." In the context of psychedelic-assisted therapy, "set" refers to a patient’s mindset, expectations, and psychological preparation, while "setting" encompasses the physical environment, the therapeutic atmosphere, and the interpersonal dynamics between the patient and the practitioners. Despite widespread acknowledgment that these factors are central to the psychedelic experience, they have historically been treated as peripheral variables rather than core components of the treatment protocol. This inconsistency has led to divergent study results, creating a significant barrier to regulatory approval and clinical adoption.
To bridge this gap, an international team of researchers convened a Delphi consensus study—a structured communication technique designed to achieve a reliable consensus among a panel of experts. The project brought together 89 experts from 17 countries, engaging them in a rigorous, multi-round debate to identify the psychosocial factors that exert the greatest influence on the efficacy of psychedelic therapy. The culmination of this effort is the Reporting of Setting in Psychedelic Clinical Trials (ReSPCT) guidelines, which were recently published in the journal Nature Medicine.
The ReSPCT guidelines consist of a 30-item checklist that serves as the first global agreement on which variables must be documented and reported in clinical trials. By establishing this benchmark, the researchers hope to transform how psychedelic studies are conducted, ensuring that the subjective experience of the patient is captured with the same precision as biological markers.
"For decades, we’ve known that psychedelics don’t work in isolation. The person’s mindset, the therapy room, even the music playing all influence outcomes," explains co-lead author Chloë Pronovost-Morgan, a researcher at McGill University and Imperial College London. "Two trials using the same psychedelic drug, at the same dose, can produce completely different results depending on the environment. If we do not account for these variables, we are effectively trying to study a complex human experience by ignoring the very context that shapes it."
This paradigm shift challenges the traditional model of pharmaceutical research. In standard clinical pharmacology, the goal is often to isolate a drug’s effects by eliminating or controlling as many outside variables as possible. This "reductionist" approach is highly effective for drugs like statins or antibiotics, where the chemical interaction is the primary driver of the outcome. However, with psychedelics, the drug is merely one component of a broader therapeutic experience. The ReSPCT guidelines acknowledge that context is not merely a "noise" variable to be suppressed, but a fundamental mechanism of action that should be measured, documented, and analyzed directly.
The lack of such standards has had tangible, real-world consequences for the field of psychiatry. The stakes were highlighted recently when the U.S. Food and Drug Administration (FDA) declined to approve MDMA-assisted therapy for the treatment of post-traumatic stress disorder (PTSD). Among the primary concerns cited by regulators was the inconsistent reporting of trial data, which made it difficult to parse the drug’s specific contribution from the influence of the therapy provided alongside it. Without a standardized language to describe the "setting," regulatory bodies struggle to verify the reproducibility and safety of the treatments.
Leor Roseman, co-senior author from the University of Exeter, emphasizes that these guidelines are essential for the maturation of the industry. "Having clear guidelines for contextual considerations is essential to understand the effects of psychedelics and how they work differently from other psychiatric medications," Roseman stated. "Our guidelines will also help in replicating results and understanding the true therapeutic potential of psychedelics. When we can speak the same language across international studies, we move from anecdotal success to robust clinical evidence."
The urgency of this work is driven by the growing public demand for alternatives to conventional psychiatric medications. Current treatments for conditions such as severe depression, treatment-resistant anxiety, and PTSD often come with significant limitations, including slow onset of action and persistent side effects. Psychedelic-assisted therapy has shown promise in providing rapid, durable relief for these conditions, yet the path to implementation remains fraught with regulatory hurdles.
"There is immense public interest in psychedelic therapies, particularly for individuals suffering from debilitating mental health conditions like PTSD, depression and anxiety, which have not responded to existing treatments," says co-senior author Kyle Greenway, an Assistant Professor in McGill’s Division of Social and Transcultural Psychiatry and a researcher at the Lady Davis Institute for Medical Research. "Our guidelines offer a new gold standard for psychedelic research, helping bring these treatments to those who need them most."
By providing a common framework for evaluating and reporting contextual variables, the ReSPCT guidelines aim to make future trial outcomes more consistent and comparable across the global scientific community. The hope is that by harmonizing how studies are reported, researchers can better understand the "active ingredients" of the therapeutic setting, such as the role of therapist rapport or the influence of specific preparation protocols.
To facilitate the adoption of these guidelines, the research team is taking active steps to integrate them into the scientific mainstream. A three-day workshop is currently being organized for October, funded by McGill’s Healthy Brains, Healthy Lives initiative. The event will bring together leading experts in psychedelics, neuroscience, and clinical psychiatry to discuss the practical implementation of the ReSPCT guidelines. The workshop will serve as a platform for determining how these standards can be seamlessly woven into research protocols and clinical practice, ensuring that the field of psychedelic science remains on a trajectory of growth and credibility.
As the medical community continues to explore the potential of these compounds, the ReSPCT guidelines represent a critical evolution in the scientific method. By finally codifying the influence of mindset and environment, researchers are not only improving the rigour of their trials but are also honoring the complex, human-centric nature of the healing process. For patients awaiting new options for their mental health, this standardized approach may prove to be the bridge that leads from experimental hope to a recognized, reliable clinical reality. The work of the international consortium underscores a clear consensus: in the world of psychedelic medicine, the context is not just part of the story—it is essential to the science.
